Idelalisib in relapsed/refractory diffuse large B-cell lymphoma:results from a Nordic Lymphoma Group phase II trial

Autor:	Judit Jørgensen, Karin Fjordén, Sara Ekberg, Peter de Nully Brown, Nevzeta Kuric, Ingemar Lagerlöf, Thomas Stauffer Larsen, Mats Jerkeman, Karin E. Smedby
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	relapsed/refractory DLBCL business.industry Hematology medicine.disease Lymphoma Idelalisib Transformed Lymphoma Clinical Trials Phase II as Topic Treatment Outcome Drug Resistance Neoplasm Purines Recurrence Retreatment Relapsed refractory medicine Cancer research Humans Lymphoma Large B-Cell Diffuse Molecular Targeted Therapy transformed lymphoma business Diffuse large B-cell lymphoma Phosphoinositide-3 Kinase Inhibitors Quinazolinones
Zdroj:	Fjordén, K, Ekberg, S, Kuric, N, Smedby, K E, Lagerlöf, I, Larsen, T S, Jørgensen, J M, de Nully Brown, P & Jerkeman, M 2022, ' Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial ', British Journal of Haematology, vol. 196, no. 2, pp. 437-440 . https://doi.org/10.1111/bjh.17792
DOI:	10.1111/bjh.17792
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79c56ed3b826d7a46616c1e34150b46 https://portal.findresearcher.sdu.dk/da/publications/8d2449fd-20cd-435e-90be-b77a4ce88ea2 Zobrazit plný text záznamu